Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Thymic Function and Immune Resilience Programs

Shots: Tolerance Bio entered into an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), for certain thymus-related indications in the Americas and Europe. The company also plans to initiate P-II studies evaluating the therapy for enhancement of thymic function Under the agreement, Tolerance Bio will advance efineptakin alfa alongside its existing thymus-focused pipeline, including biologic drugs, thymus-targeting mRNA, and thymus cell therapies. NeoImmuneTech is eligible for potential development and sales milestone payments of up to $260M, plus equity consideration and tiered royalties on net sales Efineptakin alfa has been evaluated in more than 800 subjects across 15 clinical studies, generating safety, tolerability, pharmacologic, and clinical data supporting further development Ref: Tolerance Bio | Image: Tolerance Bio | Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com The post Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Thymic Function and Immune Resilience Programs appeared first on PharmaShots.